PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026Current Medical Research and Opinion0 citations

Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis

View Full Paper
CCCatherine C. CoombsJWJennifer A. WoyachJBJennifer R. Brown

Key Points

  • This analysis aims to evaluate patient-reported outcomes during pirtobrutinib treatment in patients with mantle cell lymphoma and chronic lymphocytic leukemia.
  • Analysis from the BRUIN phase 1/2 trial.
  • Investigation of patient-reported outcomes (PROs) throughout treatment.
  • Assessment of outcome stability and improvement.
  • Most patients reported stable or improved outcomes during treatment.
  • Patient-reported outcomes demonstrated consistency over the treatment duration.

Abstract

The final analysis from the BRUIN trial demonstrates stability in PROs throughout the duration of treatment with pirtobrutinib. Most patients with CLL/SLL and MCL reported stable or improved outcomes throughout the study.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Coombs et al. (2026) studied this question.

synapsesocial.com/papers/6980fe57c1c9540dea810586https://doi.org/10.1080/03007995.2025.2607542
Ask AI
Helpful
Bookmark
Share
View Full Paper